Advanced search
Publication Cover
Infectious Diseases Volume 56, 2024 - Issue 5
Submit an article Journal homepage
206
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Host response signature trends in bacteraemia – authors’ response

Anna Maria Peria The University of Queensland, UQ Centre for Clinical Research, Brisbane, AustraliaCorrespondence[email protected]
View further author information
,
Patrick N. A. Harrisa The University of Queensland, UQ Centre for Clinical Research, Brisbane, Australia;b Herston Infectious Diseases Institute, Brisbane, Australia;c Central Microbiology, Pathology Queensland, Royal Brisbane and Women’s Hospital, Brisbane, AustraliaView further author information
&
David L. Patersona The University of Queensland, UQ Centre for Clinical Research, Brisbane, Australia;d ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore;e Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeView further author information
Pages 418-420 | Received 27 Feb 2024, Accepted 27 Feb 2024, Published online: 06 Mar 2024

References

  • Brandon R, Yager T, Cermelli S, et al. Host response signature trends in bacteraemia. Infect Dis (Lond). 2024;1–2. doi:10.1080/23744235.2024.2324072.
  • Peri AM, Rafiei N, O’Callaghan K, et al. Host response signature trends in persistent bacteraemia and metastatic infection due to Staphylococcus aureus and Gram-negative bacilli: a prospective multicentre observational study. Infect Dis (Lond). 2023;56(4):268–276. doi:10.1080/23744235.2023.2294122.
  • Australian Government Department of Health and Aged Care. Immunexpress Pty Ltd. Multiple infectious organism IVDs (430807). 2023. Available from: https://www.tga.gov.au/resources/artg/430807.
  • U.S. Food and Drug Administration. 510(k) Substantial equivalence determination decision summary SeptiCyte RAPID; 2021. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K203748.pdf.
  • von Dach E, Albrich WC, Brunel AS, et al. Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-Day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial. JAMA. 2020;323(21):2160–2169. doi:10.1001/jama.2020.6348.
  • McNamara JF, Avent M, Stewart A, et al. Evaluation of quick sequential organ failure assessment and systemic inflammatory response syndrome in patients with gram negative bloodstream infection. Infect Dis Health. 2020;25(3):151–157. doi:10.1016/j.idh.2020.01.003.
  • Eichenberger EM, Degner N, Scott ER, et al. Microbial cell-free DNA identifies the causative pathogen in infective endocarditis and remains detectable longer than conventional blood culture in patients with prior antibiotic therapy. Clin Infect Dis. 2023;76(3):e1492–e1500. doi:10.1093/cid/ciac426.
  • Peri AM, O’Callaghan K, Rafiei N, et al. Persistence of detectable pathogens by culture-Independent systems (T2 magnetic resonance) in patients with bloodstream infection: prognostic role and possible clinical implications. Clin Infect Dis. 2024;78(2):283–291. doi:10.1093/cid/ciad663.
  • López-Cortés LE, Cueto M D, Rodríguez-Baño J. How should we best treat patients with bloodstream infections? Future Microbiol. 2017;12(11):927–930. doi:10.2217/fmb-2017-0118.
  • Miller RR 3rd, Lopansri BK, Burke JP, et al. Validation of a host response assay, SeptiCyte LAB, for discriminating sepsis from systemic inflammatory response syndrome in the ICU. Am J Respir Crit Care Med. 2018;198(7):903–913. doi:10.1164/rccm.201712-2472OC.
  • de Jong NWM, van Kessel KPM, van Strijp JAG. Immune evasion by Staphylococcus aureus. Microbiol Spectr. 2019;7(2):1–27. doi:10.1128/microbiolspec.GPP3-0061-2019.
  • Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003;163(17):2066–2072. doi:10.1001/archinte.163.17.2066.
  • Ledford JG, Kovarova M, Koller BH. Impaired host defense in mice lacking ONZIN. J Immunol. 2007;178(8):5132–5143. doi:10.4049/jimmunol.178.8.5132.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.